arrow
M

Mary Cushman

University of Vermont
H指数:140
被引数:14.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism

静脉血栓栓塞症的全球负担:深静脉血栓形成和肺栓塞的发生率及结局估计

2026-09-270
PRE
Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study

疫情前慢性肾脏病与急性及后期COVID-19的关联:C4R研究

2026-06-260
OA
Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals

在640万个人中预防和评分2心血管风险方程的跨国验证

2026-05-050
OAAI
Blood mitochondrial heteroplasmic variants and cognitive performance in late midlife: REGARDS study

晚年中期线粒体异质性变异与认知表现的关系:REGARDS研究

2026-04-210
OA
ASSOCIATIONS BETWEEN PLASMA LEVELS OF COAGULATION FACTORS VIII AND IX AND INCIDENT CARDIOVASCULAR DISEASE AND MORTALITY: SYSTEMATIC REVIEW AND META-ANALYSIS

凝血因子VIII和IX血浆水平与心血管疾病发生和死亡率之间的关联:系统评价和荟萃分析

2025-09-300
PRE
Circulating biomarkers and ischemic stroke risk in adults with atrial fibrillation taking anticoagulation: the Reasons for Geographic And Racial Differences in Stroke study

循环生物标志物与接受抗凝治疗的房颤患者缺血性卒中风险:地理和种族差异卒中研究

2025-08-060
PRE
Development and Validation of Risk Models for Hospital-Acquired Bleeding in Medical Inpatients: The Medical Inpatients Thrombosis and Hemostasis (MITH) Study

医疗住院患者医院获得性出血风险模型的开发与验证:医疗住院患者血栓与止血(MITH)研究

2025-07-170
OAAI
Epigenetic mechanisms underlying variation of IL-6, a well-established inflammation biomarker and risk factor for cardiovascular disease

IL-6变异的表观遗传学机制,IL-6是一种公认的炎症生物标志物和心血管疾病的风险因素

2025-05-200
OA
Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study

先前感染的美国成年人中与抗核衣壳抗体反应SARS-CoV-2相关的人口统计学和临床因素: C4R研究

2025-03-210
OAAI
Anticoagulation and other risk factors for clinically relevant bleeding after medical hospitalization: the Medical Inpatient Thrombosis and Hemostasis Study

抗凝治疗及住院期间临床相关出血的其他危险因素:医疗住院患者血栓与止血研究

2025-03-210
PRE
On-Treatment Change in d-Dimer Is Associated With Differential Outcomes Among Therapeutic Dose Heparin-Treated Noncritically Ill Patients Hospitalized for COVID-19
2025-01-010
PRE